Text Size

A Phase 1 Study of S-3304 in Patients With Solid Tumors

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2003 by Shionogi.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Shionogi
ClinicalTrials.gov Identifier:
NCT00033215
First received: April 9, 2002
Last updated: June 23, 2005
Last verified: November 2003
History of Changes
  Purpose

To determine the maximum tolerated dose and safety profile of S-3304 in patients with biopsy accessible cancer who have failed previous therapy or to whom no standard therapies are available. To determine the pharmacokinetic profile of S-3304 in this patient population


Condition Intervention Phase
Solid Tumors
 Drug: S-3304
 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1 Study of S-3304 in Patients With Solid Tumors

Resource links provided by NLM:

MedlinePlus related topics: Cancer
U.S. FDA Resources

Further study details as provided by Shionogi:

Estimated Enrollment: 28
Study Start Date: November 2001
Estimated Study Completion Date: October 2003
  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Biopsy proven diagnosis of solid tumor(s) with biopsy accessible lesion(s)
  • Must be able to tolerate oral medication Exclusion criteria
  • Patients with other serious illnesses
  • Patients who are receiving treatments
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00033215

Locations
United States, Colorado
University of Colorado Hospital
Denver, Colorado, United States, 80262
United States, Illinois
Rush-Presbyterian-St. Lukes Medical Center
Chicago, Illinois, United States, 60612
United States, New York
Roswell Park Cancer Center
Buffalo, New York, United States, 14263
United States, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
Sponsors and Collaborators
Shionogi
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00033215     History of Changes
Other Study ID Numbers: 0110P1416
Study First Received: April 9, 2002
Last Updated: June 23, 2005
Health Authority: United States: Food and Drug Administration

Keywords provided by Shionogi:
neovascularization
matrix metalloproteinases
antiangiogenesis
type IV collagenases

Additional relevant MeSH terms:
Neoplasms

ClinicalTrials.gov processed this record on May 23, 2013